New hope for kids with lupus? early trial tests blinatumomab

NCT ID NCT06789107

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times

Summary

This early-phase study tests whether blinatumomab, a drug that targets certain immune cells, can safely improve symptoms in children with active lupus that hasn't responded to other treatments. Six participants will receive two short courses of the drug and be followed for a year. The goal is to see if it reduces disease activity and what side effects occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310051, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.